Laurence Daulhac
Overview
Explore the profile of Laurence Daulhac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jouffre B, Acramel A, Jacquot Y, Daulhac L, Mallet C
Steroids
. 2023 Sep;
200:109311.
PMID: 37734514
Chronic pain is a worldwide refractory health disease that causes major financial and emotional burdens and that is devastating for individuals and society. One primary source of pain is inflammation....
2.
Picard E, Kerckhove N, Francois A, Boudieu L, Billard E, Carvalho F, et al.
Br J Pharmacol
. 2022 Sep;
180(4):385-400.
PMID: 36131381
Background And Purpose: T-type calcium channels, mainly the Ca 3.2 subtype, are important contributors to the nociceptive signalling pathway. We investigated their involvement in inflammation and related pain-like symptoms. Experimental...
3.
Demosthenes A, Sion B, Giraudet F, Moisset X, Daulhac L, Eschalier A, et al.
Front Neurol
. 2022 Feb;
12:789432.
PMID: 35111128
Among the many symptoms (motor, sensory, and cognitive) associated with multiple sclerosis (MS), chronic pain is a common disabling condition. In particular, neuropathic pain symptoms are very prevalent and debilitating,...
4.
Kerckhove N, Boudieu L, Ourties G, Bourdier J, Daulhac L, Eschalier A, et al.
Eur Neuropsychopharmacol
. 2019 Nov;
29(12):1419-1432.
PMID: 31767519
Chronic pain is a heavy burden disease. Current treatments are generally weakly effective or associated with adverse effects. New therapeutic approaches are therefore needed. Recent studies have suggested T-type calcium...
5.
Barriere D, Boumezbeur F, Dalmann R, Cadeddu R, Richard D, Pinguet J, et al.
Br J Pharmacol
. 2019 Nov;
177(8):1773-1792.
PMID: 31734950
Background And Purpose: We previously demonstrated that paracetamol has to be metabolised in the brain by fatty acid amide hydrolase enzyme into AM404 (N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide) to activate CB receptors and TRPV1...
6.
Picard E, Carvalho F, Agosti F, Bourinet E, Ardid D, Eschalier A, et al.
Br J Pharmacol
. 2019 Feb;
176(7):950-963.
PMID: 30714145
Background And Purpose: Abdominal pain associated with low-grade inflammation is frequently encountered in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) during remission. Current treatments are not very effective...
7.
Morel V, Joly D, Villatte C, Dubray C, Durando X, Daulhac L, et al.
PLoS One
. 2016 Apr;
11(4):e0152741.
PMID: 27050431
Background: Neuropathic pain following surgical treatment for breast cancer with or without chemotherapy is a clinical burden and patients frequently report cognitive, emotional and quality of life impairment. A preclinical...
8.
Ferrier J, Bayet-Robert M, Dalmann R, El Guerrab A, Aissouni Y, Graveron-Demilly D, et al.
J Neurosci
. 2015 Dec;
35(50):16418-30.
PMID: 26674867
Significance Statement: Our study describes a decrease in cholinergic neurotransmission in the posterior insular cortex in neuropathic pain condition and the involvement of M2 receptors. Targeting these cortical muscarinic M2...
9.
Dalmann R, Daulhac L, Antri M, Eschalier A, Mallet C
Neuropharmacology
. 2014 Dec;
91:63-70.
PMID: 25448494
Paracetamol (acetaminophen) is the most commonly used analgesic in the world. Recently, a new view of its action has emerged: that paracetamol would be a pro-drug that should be metabolized...
10.
Morel V, Pickering G, Etienne M, Dupuis A, Privat A, Chalus M, et al.
Fundam Clin Pharmacol
. 2014 Apr;
28(6):671-80.
PMID: 24702319
N-methyl-D-aspartate receptor (NMDAR) antagonists may be given in persistent neuropathic pain, but adverse events especially with ketamine may limit their clinical use. Less central and cognitive adverse events are described...